STOCK TITAN
  1. Home
  2. Sec-filings
  3. PPCB
  4. [EFFECT] Propanc Biopharma, Inc. SEC Filing

[EFFECT] Propanc Biopharma, Inc. SEC Filing

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
EFFECT

Rhea-AI Filing Summary

Analyzing...
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Notice of Effectiveness
Effectiveness Date: February 24, 2026 12:00 P.M.
Form: S-1
CIK: 0001517681
Company Name: Propanc Biopharma, Inc.
File Number: 333-293147

Source: View Original Filing on SEC EDGAR

Stock PPCB logo
Propanc Bio

NASDAQ:PPCB

PPCB Rankings

#6834 Ranked by Market Cap
N/A Ranked by Dividends

PPCB Latest News

Feb 18, 2026
Propanc Biopharma Provides Corporate Update and Reports Half Yearly 2025/26 Results
Feb 5, 2026
Propanc Biopharma Unveils PRP: A Game-Changing Proenzyme Therapy Poised to Challenge Standard Cancer Treatments in the $3+ Billion Pancreatic Cancer Market
Jan 27, 2026
Propanc Biopharma Accelerates IP Momentum: Files Fourth Provisional Patent Application in Just Two Months – Strengthening Global Protection for Breakthrough Proenzyme Formulations
Jan 20, 2026
Propanc Biopharma Files New Provisional Patent Application for Methods of Producing Trypsinogen & Chymotrypsinogen with IP Australia
Jan 15, 2026
Propanc Biopharma Explains How PRP Could Impact Pancreatic Cancer

PPCB Latest SEC Filings

Feb 26, 2026
[8-K] Propanc Biopharma, Inc. Reports Material Event
Feb 19, 2026
[S-1/A] Propanc Biopharma, Inc. Amends IPO Registration Statement
Feb 17, 2026
[10-Q] Propanc Biopharma, Inc. Quarterly Earnings Report
Feb 2, 2026
[S-1] Propanc Biopharma, Inc. Files IPO Registration Statement
Jan 29, 2026
[424B3] Propanc Biopharma, Inc. Prospectus Filed Pursuant to Rule 424(b)(3)

PPCB Stock Data

3.10M
7.51M
Biotechnology
Pharmaceutical Preparations
Link
Australia
CAMBERWELL, VICTORIA